These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 21888261)

  • 1. Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
    Gertz MA; Buadi FK; Hayman SR
    Oncology (Williston Park); 2011 Jun; 25(7):620-6. PubMed ID: 21888261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we treat systemic light-chain amyloidosis.
    Chaulagain CP; Comenzo RL
    Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.
    Meier-Ewert HK; Sanchorawala V; Berk J; Finn KT; Skinner M; Seldin DC; Ruberg FL
    Amyloid; 2011 Jun; 18 Suppl 1():130-1. PubMed ID: 21838460
    [No Abstract]   [Full Text] [Related]  

  • 7. Who knows how to treat systemic light chain amyloidosis?
    Comenzo RL
    Oncology (Williston Park); 2011 Jun; 25(7):626, 628-9, 632-3. PubMed ID: 21888262
    [No Abstract]   [Full Text] [Related]  

  • 8. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.
    Schonland SO; Perz JB; Hundemer M; Hegenbart U; Kristen AV; Hund E; Dengler TJ; Beimler J; Zeier M; Singer R; Linke RP; Ho AD; Goldschmidt H
    Transplantation; 2005 Sep; 80(1 Suppl):S160-3. PubMed ID: 16286897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell transplantation for immunoglobulin light chain amyloidosis.
    Sher T; Gertz MA
    Curr Probl Cancer; 2017; 41(2):129-137. PubMed ID: 28457657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Sher T; Dispenzieri A; Gertz MA
    Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin light chain amyloidosis.
    Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
    Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Advances in the Management of Cardiac Amyloidosis.
    Vranian MN; Sperry BW; Valent J; Hanna M
    Curr Cardiol Rep; 2015 Nov; 17(11):100. PubMed ID: 26374453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
    Sanchorawala V
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.